Business Context and Reporting Period
This Form 8-K is a Current Report filed by NanoVibronix, Inc. (not Envue Medical, Inc.) on November 19, 2025. The registrant is incorporated in Delaware and trades on the Nasdaq Capital Market under the symbol NAOV. The report primarily serves to furnish a Shareholder Letter dated November 19, 2025, under Item 7.01 (Regulation FD).
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural filing to disclose the issuance of a shareholder letter and does not contain a financial statement or earnings release within the provided text.
Material Changes
No material financial changes versus a prior comparable period are detailed in this filing. The report notes the issuance of a Shareholder Letter but does not summarize its contents or disclose specific operational or financial changes in the body of the 8-K.
Guidance, Outlook, and Risks
The filing states that the information, including the attached Shareholder Letter (Exhibit 99.1), is furnished pursuant to Item 7.01 and is not deemed "filed" for purposes of Section 18 of the Exchange Act. Consequently, it is not subject to the liabilities of that section nor incorporated by reference in other filings. No specific guidance, outlook, or risk factors are enumerated in the text of this report.
Investor Verification Checklist
- Verify the correct registrant name: The filing is for NanoVibronix, Inc., not Envue Medical, Inc.
- Review Exhibit 99.1 (Shareholder Letter) directly, as the substantive content of the communication is not summarized in the 8-K body.
- Confirm that the Shareholder Letter is not incorporated by reference into other SEC filings, as explicitly stated in Item 7.01.
- Check the Nasdaq Capital Market listing status for ticker NAOV.